Physician profile
Michael Snell
NPI 1215158423
$1,906.47
in general payments reported to CMS, 2019-2025
26 companies · $90.84 in 2025
The $90.84 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $159 · 2022: $254 · 2023: $200 · 2024: $24.17 · 2025: $90.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $200 · Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $199.94 |
| Food and Beverage | $115.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $271.68 | 2020-2023 | |
| Janssen Biotech, INC. | $236.46 | 2019-2025 | Rybrevant, Carvykti |
| Incyte Corporation | $185.19 | 2019-2020 | |
| Pfizer INC. | $151.76 | 2019-2022 | |
| Genentech USA, INC. | $147.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $109.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $104.28 | 2019-2020 | |
| Exelixis INC. | $65.28 | 2019 | |
| Clovis Oncology, INC. | $64.40 | 2019 | |
| Tesaro, INC. | $57.87 | 2019 | |
| Amgen INC. | $53.37 | 2019 | |
| Alexion Pharmaceuticals, INC. | $45.66 | 2019-2022 | |
| Genzyme Corporation | $35.23 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $35.02 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $29.25 | 2022 | |
| Emd Serono, INC. | $25.00 | 2019 | |
| Abbvie INC. | $24.17 | 2024 | |
| Agios Pharmaceuticals, INC. | $23.98 | 2019 | |
| Gilead Sciences, INC. | $23.38 | 2019 | |
| Eisai INC. | $20.46 | 2019 | |
| Lilly USA, LLC | $18.21 | 2019 | |
| Eusa Pharma (US) LLC | $16.90 | 2019 | |
| Merck Sharp & Dohme LLC | $14.92 | 2019 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Snell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.